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Abstract
Background: Diabetic neuropathy is a common neuropathy associated with paresthaesia and pain. The
mechanisms underlying the painful conditions are not well understood. The aim of this study is to investigate the
participation of purinergic P2X3 receptors in painful diabetic neuropathy.
Results: Diabetes was induced by an intraperitoneal injection of streptozotocin (STZ). We showed that mechanical
allodynia was induced two weeks after a STZ injection and lasted for at least another seven weeks. The mechanical
allodynia was significantly attenuated by peripheral administration of the P2X receptor antagonists, PPADS or TNP-
ATP. DiI was subcutaneously injected into the rat hindpaw to label hindpaw-innervated dorsal root ganglion (DRG)
neurons. ATP activated fast-inactivating P2X3 receptor-mediated currents in the labeled DRG neurons were studied.
ATP responses in STZ-treated rats were ~2-fold larger than those in control rats. Furthermore, the expression of
P2X3 receptor proteins in the plasma membrane of L4-6 DRGs of STZ rats was significantly enhanced while the
total expression of P2X3 receptors remained unaltered.
Conclusions: These results indicate that a large enhancement of P2X3 receptor activity and an increase in the
membrane expression of P2X3 receptors contribute to the development of chronic pain in STZ-induced diabetic
rats and suggest a possible target for the treatment of diabetic neuropathic pain.
Background
Diabetics mellitus is a debilitating chronic disease that
affects ~8% of the population in the US. About ~70% of
diabetic patients are reported to have various forms of
nerve damage (neuropathy). The most common type of
diabetic neuropathy is nerve damages in the periphery,
e.g., hands, toes and feet. Peripheral neuropathy patients
often experience aberrant pain sensation, including
spontaneous pain, hyperalgesia (severe pain with mild
painful stimuli) and allodynia (pain with innocuous sti-
muli, e.g. light touch) [1-6]. Treatment options for these
abnormal sensations have been limited, partly because
of our poor understanding of the molecular mechanisms
underlying the diabetes-induced neuropathic pain.
Sensitization of dorsal root ganglion neurons and their
associated nerve fibers has been suggested to be a major
cause of diabetes-induced abnormal pain [4,7]. Changes
in the expression or function of T-type Ca
2+ channels
[7] and transient receptor potential vanilloid 1 (TRPV1)
receptors [6,8] are thought to contribute to changes in
the activity of sensory neurons under diabetic
conditions.
P2X receptors (P2XRs) are ligand-gated cationic chan-
nels abundantly expressed in the pain processing DRG
neurons [9-11]. There is growing evidence that P2XR
expression and function in DRGs are greatly sensitized
after tissue inflammation [12,13] and nerve injury [14].
Thus, P2XRs play a pivotal role in the transmission of
nociceptive information under injury conditions
[9,15,16]. ATP and noradrenaline are co-stored and co-
released from sympathetic nerves [17]. EctoATPase,
which hydrolyzes extracellular di- and triphosphate
nucleotides, modulates purinergic transmission [17]. It
has been established that ATP and purinergic receptors
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any medium, provided the original work is properly cited.are involved in peripheral signaling in diabetic rats. Sti-
mulation of sympathetic nerves in those rats causes C-
fiber polymodal receptor units to fire [18]. An increase
in the extracellular level of adenosine by an adenosine
kinase inhibitor attenuates diabetes-induced tactile allo-
dynia [19]. Studying the involvement of P2XRs in pain-
ful diabetic neuropathy, Migita et al (2009) [20] found
that P2X receptor antagonists inhibit the STZ-induced
mechanical allodynia in mice and the levels of P2X2R
and P2X3R mRNA in DRGs are increased. The molecu-
lar mechanism underlying the change in P2XR-mediated
activity, however, has not been investigated. We there-
fore studied P2X3R current activity of hindpaw inner-
vated DRG neurons in STZ-induced diabetic rats. Total
and membrane expressions of the P2X3R protein were
also investigated. We found that following the develop-
ment of diabetes, P2X3R-mediated current activity is
greatly enhanced and the membrane, but not the total,
expression of P2X3Rs is significantly upregulated.
Materials and methods
Induction of diabetes
All experiments were approved by the Institutional Ani-
mal Care and Use Committee at the University of Texas
Medical Branch and were in accordance with the guide-
lines of the International Association for the Study of
Pain. Male Sprague-Dawley rats weighing 190-220 g
were used in our experiments. Diabetes were induced by
a single injection of streptozotocin (STZ; 70 mg/kg i.p.,
Sigma Chemicals, St. Louis, MO), which was freshly dis-
solved in 0.9% sterile saline as described [4,21-23]. Two
weeks later, diabetes was confirmed by measurements of
blood glucose concentrations in samples obtained from
the tail vein. Only rats with blood glucose concentration
> 350 mg/dl and mechanical paw withdrawal threshold
(PWT) < 5 g were further used in the study.
Cell labeling
Hindpaw receptive field specific DRG neurons were
labeled by injection of 1,19-dioleyl-3,3,39,3-tetramethy-
lindocarbocyanine methanesulfonate (DiI; Invitrogen,
Carlsbad, California) into the skin of rat hindpaws. Ani-
mals were anesthetized with a cocktail of ketamine (80
mg/kg) and xylazine (5-10 mg/kg, intraperitoneally). DiI
(25 mg in 0.5 ml methanol) was injected into the plantar
skin of bilateral hindpaws (2 μl/site, 4-6 sites in each
hindpaw). To prevent leakage, needle was left in place
for 1 min for each injection. Two weeks later, bilateral
L4-L6 DRGs in control and STZ rat groups were dis-
sected out for patch clamp recordings.
Whole-cell patch clamp recordings
As described previously [24], L4-L6 DRGs were dis-
sected out and incubated in oxygenated dissection
solution with enzymes (collagenase D, 1.5-1.8 mg/ml
and trypsin, 1.2 mg/ml; Sigma) for 1.5 hr at 34.5°C. The
dissection solution contained (mM): NaCl 130; KCl 5;
KH2PO4 2; CaCl2 1.5; MgSO4 6; glucose 10; and HEPES
10; pH 7.2; osmolarity 305 mOsm. DRGs were then
taken from the enzyme solution, washed, and trans-
ferred to the dissection solution containing DNase (0.5
mg/ml). A cell suspension was subsequently obtained by
repeated trituration through a series of flame-polished
glass pipettes. Cells were then plated onto acid-cleaned
glass coverslips. One coverslip containing adherent DRG
cells was put into a small recording chamber (0.5 ml
volume) attached to the stage of an inverting micro-
scope (Olympus IX71, Tokyo, Japan), which was fitted
with both fluorescent and phase objectives. DiI-labeled
neurons were identified by the bright red fluorescence
in the cytoplasm. ATP-evoked currents were recorded
in the external solution, containing (mM): NaCl 130,
KCl 5, KH2PO4 2, CaCl2 2.5, MgCl2 1, HEPES 10, glu-
cose 10 (pH = 7.2, adjusted with NaOH, osmolarity =
295-300 mOsm). Unless indicated, patch-clamp pipettes
had a resistance of 3-5 MΩ when filled with the pipette
solution containing (mM): potassium gluconate 140,
NaCl 10, HEPES 10, glucose 10, BAPTA 5 and CaCl2 1
(pH = 7.25 adjusted with KOH; osmolarity = 295
mOsm). ATP-induced currents were filtered at 2-5 kHz
and sampled at 50 or 100 μsec per point.
Measurement of hindpaw withdrawal threshold
Experiments were performed on STZ-treated rats and
age-matched control rats. The mechanical threshold was
determined before and after STZ or saline injection. To
quantify the mechanical sensitivity of the hindpaw, rats
were placed in individual plastic boxes and allowed to
acclimate for > 30 min. Rat hindpaw PWTs in response
to the stimulation of Von Frey filaments were deter-
mined. A series of calibrated von Frey filaments (ranging
from 0.4 to 15.0 g) were applied perpendicularly to the
plantar surface of the hindpaw with a sufficient force to
bend the filaments for 60s or until paw withdrew. In the
presence of a response, the filament of next lower force
was applied. In the absence of a response, the filament of
next greater force was applied. To avoid injury during
tests, the cutoff strength of the von Frey filament was 15
g .T h et a c t i l es t i m u l u sp r o d u c i n ga5 0 %l i k e l i h o o do f
withdrawal was determined using the “up-down” method
[25]. Each trial was repeated 2-3 times at approximately 2
min intervals. The mean value was used as the force pro-
duced a withdrawal response. All behavioral studies were
performed under blind conditions.
Drug application
The P2XR antagonist, PPADS and TNP-ATP (Sigma, St.
Louis, MO) were used in this study. PPADS (25 mmol)
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taneously injected to the plantar surface of a rat hindpaw.
For control, the same volume of phosphate balanced sal-
ine (PBS), instead of an antagonist, was injected. Follow-
ing the injection, one PWT measurement was obtained
every 10 min for a period of 90 min. For patch clamp
recordings, ATP (20 μM) was pressure delivered (1-2 psi)
to the recorded cell through a two-tube applicator. One
tube contained the ATP or ATP+antagonist solution and
the other tube contained a wash solution devoid of ATP.
Each tube was connected to a solenoid valve, which was
controlled by computer pulses to start and stop the solu-
tion flow. The exchange rate was fast and would not limit
peak ATP responses [12].
Western blotting analysis
The expressions of P2X3Rs in L4-L6 DRGs from control
and STZ-treated rats were measured using Western blot
analyses [12]. The rats were euthanized by an overdose
of pentobarbital. Lumbar DRGs from both sides of
spinal cord were quickly dissected out and put into oxy-
genated dissection solution. To determine the expres-
sion of P2X3Rs on cell surface, DRGs were incubated
with Sulfo-NHS-LC-Biotin (1 mg/ml, Pierce) for 30 min
on ice as described [24]. Since biotin is impermeable to
the cell membrane, only proteins on the cell surface
were biotinylated. The unbound biotin in the solution
was removed by 5 × wash of DRGs. DRGs were then
homogenized in buffer A (Pierce) and centrifuged at
13,500 × g (4°C) for 12 min. A 200 μg protein sample
was incubated with streptavidin beads (20 μl, Sigma) for
3 h at 4°C. The beads were washed 3 × with RIPA buf-
fer and precipitated by centrifugation and collected.
Sample buffer (50 μl) was added to the collected beads
and boiled for 3 min. Beads were pelleted again by cen-
trifugation and the supernatant was collected. The
supernatant was diluted to the same volume as the
starting material (i.e., 200 μg total protein). Equal
volume of total and membrane samples was applied to
SDS-PAGE. Membranes were incubated with various
primary and secondary antibodies. Antibodies used were
anti-P2X3Rs (1:1000 Neuromics, Minneapolis) and anti-
extracellular signal-regulated kinase 1 (anti-ERK1)
(1:1500, Pierce). Immunoreactive proteins were detected
by enhanced chemiluminescence (ECL kit, Amersham-
Pharmacia Biotech). The densities of protein bands were
analyzed using NIH image software.
Data analysis
All data were expressed as mean ± SEM. The Student’st
test was used to assess significance of changes between
two groups. A P value < 0.05 was considered statistically
significant.
Results
STZ induces long-term mechanical allodynia in rats
STZ has been widely used to induce type 1 diabetes in
rodents for the study of pain associated with diabetic
neuropathy [4,22,23]. Following a single i.p. injection of
STZ (70 mg/kg), we monitored rat blood glucose, body
weight and PWT for nine weeks. A majority of the rats
(66.7%, n = 68) developed hyperglycemia after STZ
treatment. Only rats with a blood glucose concentration
> 350 mg/dl were used in further studies. Blood glucose
reached the final elevated level two weeks after STZ
injection and maintained elevated for at least another 7
weeks (Figure 1A). The diabetic rats also displayed poly-
uria and an increase in food and water intake (data not
shown). Compared with saline-injected rats, the growth
rate of STZ rats was noticeably reduced (Figure 1B). In
parallel with elevated blood glucose levels, STZ rats also
developed mechanical allodynia when tested with von
Frey filaments (Figure 1C). The mechanical PWT was
11.2 ± 0.8 g (n = 15) prior to STZ injection, decreased
substantially (3.5 ± 0.6 g, n = 15) two weeks after the
injection and remained at the reduced level for another
7-week test period (Figure 1C).
STZ-induced mechanical allodynia is mediated by P2X
receptors
T od e t e r m i n ei fi o n o t r o p i cP 2 X R sa r ei n v o l v e di nt h e
development of allodynia in STZ rats, the P2XR antago-
nist, PPADS or TNP-ATP was injected into the plantar
surface of rat hindpaw and its effects on PWTs were
determined. Application of PPADS (25 mmol/50 μl), an
antagonist for P2X1, P2X2, P2X3 P2X4 and P2X5 recep-
tors [26], significantly increased PWTs for > 20 min (Fig-
ure 2A). In contrast, an application of PBS had no effect
on PWTs of STZ-injected rats. To further determine the
specific P2XRs in diabetes-induced allodynia, the effect
of the potent P2X1, P2X3, P2X2/3 receptor antagonist,
TNP-ATP [27], was tested. Following an application of
TNP-ATP (50 mmol/50 μl) to the hindpaw of STZ rats,
PWTs increased and the effect persisted for > 30 min (n
= 8, Figure 2B). Since TNP-ATP has no significant effects
on PWTs in control rats [14], those P2XRs do not nor-
mally participate in the responses to von Frey filament
s t i m u l a t i o ni nt h eh i n d p a w .T a k e nt o g e t h e r ,t h e s ed a t a
suggest that P2X1, P2X3 and/or P2X2/3 receptors are
sensitized and involved in the development of diabetes-
induced allodynia.
P2X3R-mediated fast-inactivating ATP currents in
hindpaw-innervated DRG neurons are enhanced in STZ-
rats
We then determined the P2XR-mediated current
responses in STZ rats. Since the expression of P2X1R
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heteromeric P2X2/3 are likely the P2XRs sensitized by
the STZ treatment. ATP-evoked homomeric P2X3R-
mediated currents in single lumbar (L4-6) DRG neu-
rons innervating the hindpaw were measured using
patch recording techniques. Since lumbar DRGs, e.g.,
L6 DRG, contain neurons innervating different organs/
tissues, including the skin and colon, Dil was injected
into the skin of the rat hindpaw immediately prior to
the saline or STZ injection. Labeled hindpaw-inner-
vated DRG neurons were identified and recorded 2
weeks later (Figure 3). At holding potential of -60 mV,
ATP (20 μM) evoked fast inactivating currents in the
majority of DiI-labeled DRG neurons isolated from
both control (Figure 3B, left) and STZ-treated rats
(Figure 3C, left). The ATP-evoked fast inactivating cur-
rents were completely blocked by TNP-ATP (100 nM)
in both control and STZ-treated DRG neurons (Figures
3B and 3C, middle), suggesting that the current
responses are P2X3R mediated. We then measured the
amplitude of P2X3R-mediated ATP currents in DRG
neurons and found that the ATP currents were signifi-
cantly enhanced in DiI-labeled DRG neurons isolated
from STZ rats (Figure 4). The average peak current
density of P2X3Rs obtained from DRG neurons of STZ
r a t sw a s1 3 . 6±1 . 5p A / p F( n = 12), which is 2.3-fold
larger than the peak current density, i.e., 6.0 ± 1.3 pA/
pF (n = 15), measured in DRG neurons of control rats.
Thus, P2X3R-mediated fast-inactivating ATP currents
in hindpaw-innervated DRG neurons are greatly poten-
tiated after STZ treatment and contribute to STZ-
induced allodynia.
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Figure 1 Hyperglycemia and mechanical allodynia observed in
STZ-induced diabetic rats. (A) Following a single i.p. injection of
STZ, the blood glucose level was significantly enhanced two weeks
later. The enhancement persisted for at least another 7 weeks. (B)
The growth rate of STZ rats was reduced. The body weight of
control rats exhibited a steady increase, whereas the body weight
of STZ rats remained unchanged. (C) PWTs in response to von Frey
filament stimulation were significantly lowered two weeks after the
STZ injection. The mechanical allodynia lasted for at least another 7
weeks. Data points are expressed as mean ± S.E.M. Error bars
smaller than the size of the symbol are not shown. (*P < 0.05 vs.
control, n = 12-15).
A
B
Figure 2 P2XR antagonists significantly reduce STZ-induced
mechanical allodynia. The effects of the subcutaneously
administrated P2XR antagonists (A) PPADS and (B) TNP-ATP on
PWTs were studied in rats two weeks after a STZ injection. The
PWTs measured in the presence of antagonists were significantly
larger than those measured in PBS. Thus, the P2XR antagonists
partially reversed the mechanical allodynia induced by the STZ
treatment. (*P < 0.05, n = 8-10).
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in STZ rats
To determine the molecular mechanism underlying the
STZ-induced enhancement of ATP currents in DRG
neurons, both total and membrane expressions of
P2X3Rs in DRGs in control and STZ-treated rat groups
were determined using Western blotting analyses two
weeks after either a saline or STZ injection. STZ injec-
tion did not alter the total P2X3R expression in DRGs
(Figures 5A and 5C). On the other hand, the expression
of membrane P2X3 receptors was significantly higher in
the STZ rat group (Figures 5B and 5C). The membrane/
total P2X3R expression ratio increased by 85.6% after
STZ treatment (Con: 18.1 ± 0.8%, STZ: 33.6 ± 5.8%, n =
5, *p < 0.05, Figure 5D). Thus, the trafficking of P2X3
receptors to the cell surface membrane in hindpaw-
innervated DRG neurons is greatly enhanced in diabetic
rats.
Discussion
In this study, we show that a single injection of STZ can
induce diabetes and mechanical allodynia in rats two
weeks later. The conditions were maintained for at least
another seven weeks (Figure 1). The STZ-induced
mechanical allodynia is blocked by the specific P2XR
antagonists PPADS and TNP-ATP (Figure 2), an
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Figure 3 P2X3R-mediated ATP currents in Dil-labeled DRG
neurons. A. An example of a Dil-labeled DRG neuron (Left). A phase
image of the same DRG neuron is shown on the right. Examples of
fast-inactivating P2X3R-mediated ATP currents evoked in hindpaw-
innervated Dil-labeled neurons isolated from L4-6 DRGs of control
(B) and STZ-treated (C) rats. The solid line above each trace indicates
the period of an application of 20 μM ATP or ATP+TNP-ATP (100
nM). The membrane was held at -60 mV. TNP-ATP completely
blocked the fast-inactivating ATP currents obtained from both
control and STZ -treated rats. The block was partially reversed
following a 3 min washout of TNP-ATP.
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Figure 4 STZ treatment potentiates fast-inactivating ATP
currents. A, Examples of fast-inactivating ATP currents in Dil-labeled
DRG neurons isolated from control (left) and STZ-treated (right)r a t s .
The amplitude of ATP currents obtained from STZ-treated rats was
much larger than that obtained in control rats. B, Mean peak ATP
current densities. The mean peak current density of the fast-
inactivating ATP currents measured in DRG neurons of STZ rats was 2.2
times larger than that measured in DRG neurons of control rats (Con,
6.3 ± 1.5 pA/pF, n =1 5 ;S T Z ,1 3 . 8±2 . 3p A / p F ,n=12; *p <0 . 0 5 ) .
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Figure 5 STZ treatment enhances the membrane protein
expression of P2X3Rs. (A) Total and (B) membrane expression of
P2X3R proteins in DRGs of control and STZ-treated rats. The total
P2X3R protein expressions were normalized with their respective
ERK1. The low expression of ERK1 in membrane fractions suggests a
minimal contamination of cytoplasmic P2X3Rs in protein samples.
(C) The total expression of P2X3Rs did not change with STZ
treatment. On the other hand, the expression of membrane P2X3Rs
was significantly increased (*P < 0.05, n = 5). (D) Membrane/total
ratio of P2X3R expression. The membrane expression of P2X3Rs was
normalized to the total P2X3R expression in its respective rat group.
The membrane/total P2X3R expression ratio in control rats was 18.1
± 0.8% (n = 5) in control rats and was 33.6 ± 5.8% (n = 5) in STZ
rats. The membrane expression of P2X3Rs was significantly
enhanced with STZ treatment (P < 0.05).
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involvement in a mouse model of diabetes [20]. We
further showed that the same dose of ATP evokes much
larger P2X3R-mediated inward currents in Dil-labeled
hindpaw-innervated DRG neurons isolated from STZ
treated rats than those isolated from control rats (Figure
4). The expression P2X3Rs in the cell membrane of
STZ primary sensory neurons is significantly upregu-
lated (Figure 5). Thus, P2X3R sensitization is a major
contributor to STZ-induced mechanical allodynia. To
the best of our knowledge, this is the first report show-
ing an enhancement of P2X3R trafficking to the cell
membrane of hindpaw-innervated primary sensory neu-
rons in a painful diabetic rat model.
P2XR sensitization have been implicated in abnormal
pain signaling in a variety of injuries [13,29-31], includ-
ing inflammation [12], sciatic nerve ligation [14,32],
burn injury [33] and chronic compression of DRGs [34].
The results of this study and of Migita et al [20] provide
the evidence that P2X3R signaling also plays a key role
in chronic pain produced by diabetic neuropathy.
TNP-ATP is a potent antagonist for P2X1, P2X3 and
P2X2/3 receptors. Because of the low expression of
P2X1 receptors in DRGs [13,28,35,36], the complete
block of P2X3R-mediated ATP currents by TNP-ATP
(Figure 3) and the upregulation of cell membrane traf-
ficking of P2X3Rs in DRG neurons (Figure 5), we con-
clude that P2X3-containing receptors play a critical role
in the development of abnormal pain state following
STZ injection. Our study concentrated on diabetes-
induced changes in fast-inactivating P2X3R currents.
Since P2X2R mRNA was also found to increase after
STZ treatment [20], it is of interest to determine, in the
future, if slow-inactivating P2X2/3R-mediated currents
in Dil-labeled DRG neurons are altered by STZ-induced
diabetes. Our conclusion is consistent with the observa-
tion that the P2X3R antagonist, A-317491, applied sub-
cutaneously, blocks the mechanical allodynia elicited by
nerve injuries [30]. The results also support our pre-
vious observation that the P2X3R participates in neuro-
pathic pain in the periphery [14]. In contrast, P2X4/
P2X7 receptors in microglia were reported to mediate
the neuropathic pain disorders in the spinal cord
[37-39].
We showed that TNP-ATP reversed STZ-induced
mechanical allodynia partially (Figure 2). The incom-
plete block of the behavioral responses could be a result
of less than saturating concentration of the antagonist
used in these experiments. Further experiments are
needed to determine the dose response and the maximal
effect of the antagonist. In addition, other receptors or
channels, e.g. TRPV1 receptors [6,8], T-type Ca
2+ chan-
nel upregulation could also participate in producing dia-
betic nociception. In addition to receptor sensitization,
an increase in endogenous ATP after STZ treatment
could also give rise to the increase in P2XR-mediated
allodynia (Figure 2). Our observation that ATP is
released from both DRG neurons and glial satellite cells
in DRGs [40] have led us to suggest that the origin of
ATP release in the hindpaws of STZ rats stems from
peripheral nerve terminals and their surrounding glial
and immune cells. We measured ATP release in the rat
hindpaw following spared nerve injury and found that
ATP release was increased only when a stiff (13.5 g) von
Frey filament was used for stimulation, but not when a
low-strength filament (3.5 g) was applied [14]. Based on
the study and the use of low-strength von Frey filaments
in diabetic rat experiments (Figure 2), we suggest that
an increase in ATP release is not likely the major cause
for the observed increase in STZ-induced allodynia. We
will test if this is indeed the case in our future study of
the role of ATP in diabetes.
The P2X3R expression and trafficking are of great
interest in understanding the increase in receptor func-
tion under conditions of peripheral inflammation and
neuropathy. Changes in the total expression of P2X
receptors have been found to vary among nerve injury
models. It has been reported that P2X3R expression in
DRGs increases after chronic constriction injury [41],
decreases when the sciatic or spinal nerves are ligated
[42,43], or remains unchanged in spared nerve injury
model [14]. The reason for the different observations
has not been investigated. The varying findings could
simply be a result of different population of neurons in
a ganglion affected by different nerve injury models.
Migita et al (2009) [20] reported that expression of
P2X2 and P2X3 receptor mRNA was upregulated in
STZ-induced diabetic mice. They did not study the
expression of these receptors at the protein level. Here,
we show that STZ treatment does not alter the expres-
sion of total P2X3R protein (Figure 5A) but enhances
the membrane expression of the receptor (Figure 5C) in
rats. In our experiments, the large (2.2-fold) increase in
P2X3R-mediated currents following STZ-induced dia-
betes cannot be entirely accounted for by the increase
(85.7%) in P2X3R trafficking. Nevertheless, the relation-
ship between biochemical and electrophysiological or
behavioral measurements is not necessarily linear. Other
factors, e.g. changes in the modulation of the receptor
by protein kinases [24] or changes in channel properties
[12], could also contribute to an increase in the P2X3R
function. The mechanism underlying the increase in
trafficking of P2X3Rs following diabetes has yet to be
determined. Our data do indicate that mechanisms
involved in P2XR-mediated neuropathic pain and
inflammatory pain are distinct. Following CFA-induced
peripheral inflammation, the total P2X3R expression has
been found to be upregulated [12].
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diabetes promotes the trafficking of P2X3Rs to the
membrane of DRG neurons and thus increases P2X3R-
mediated responses. The change enhances the activity of
afferent neurons and contributes to abnormal diabetes-
induced peripheral neuropathic pain. The results may
provide promising clues for the development of new
therapeutic strategies for managing intractable neuro-
pathic pain in patients with diabetes.
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